Federal Judge Dismisses Two Allergan Units from Botox Patent Infringement Lawsuit

A federal judge in Delaware has ruled to dismiss two Allergan entities from a lawsuit concerning alleged patent infringement tied to Botox products. The core issue revolved around claims that two biotechnology firms had infringed upon these patents. According to the filings, one Allergan unit could not convincingly demonstrate its status as the exclusive licensee for the patents in question. Meanwhile, another unit consented to withdrawal from the litigation. For more detailed information, visit the original report on Law360.